Systematic Review on Epstein-Barr Virus (EBV) DNA in Diagnosis of Nasopharyngeal Carcinoma in Asian Populations |
Han, Bao-Lin
(Tianjin Baodi Hospital)
Xu, Xiang-Ying (Tianjin Baodi Hospital) Zhang, Chun-Zhi (Tianjin Huan Hu Hospital) Wu, Jian-Juan (Tianjin Huan Hu Hospital) Han, Chun-Feng (Tianjin Baodi Hospital) Wang, Hui (Tianjin Baodi Hospital) Wang, Xuan (Tianjin Baodi Hospital) Wang, Guang-Shun (Tianjin Baodi Hospital) Yang, Shu-Juan (West China School of Public Health, Sichuan University) Xie, Yao (West China School of Public Health, Sichuan University) |
1 | Leung SF, Tam JS, Chan AT, et al (2004). Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem, 50, 339-45. DOI |
2 | Liao LY, Kong M, Liu CJ (2010). Comparison of detection of white blood cell's EBV DNA and plasma's VCA-IgA in nasopharyngeal carcinoma patients. Med Innov China, 7, 145-6. |
3 | Lin JC, Chen KY, Wang WY, et al (2001). Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol, 19, 2607-15. |
4 | Lo YMD, Chan LY, Chan AT, et al (1999). Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res, 59, 5452-5. |
5 | Lo YMD, Chan LYS, Lo KW, et al (1999). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 59, 1188-99. |
6 | Lo YMD, Leung S, Chan LY, et al (2000). Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res, 60, 2351-5. |
7 | Luo YL, Ou GP, Chi PD, et al (2009). Combined determination of Epstein-barr virus related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Chinese Journal of China, 28, 96-9. |
8 | Mai S, Zong Y, Zhang M, et al (2002). Detection of Epstein-Barr virus DNA in plasma/serum: a useful serological indicator for diagnosis of nasopharyngeal carcinoma. Chin Med J, 115, 1895-7. |
9 | Mutirangura A, Pornthanakasem W, Theamboonlers A, et al (1998). Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res, 4, 665-9. |
10 | Wei WI, Sham JS, Zong YS, et al (1991). The efficacy of fiberoptic endoscopic examination and biopsy in the detection of early nasopharyngeal carcinoma. Cancer, 67, 3127-30. DOI ScienceOn |
11 | Yang X, Goldstein AM, Chen CJ (2006). Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer, 118, 780-4. DOI |
12 | Zeng Y, Zhang LG, Li HY, et al (1982). Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer, 29, 139-41. DOI |
13 | Zeng Y, Zhang LG, Wu YC, et al (1985). Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer, 36, 545-7. DOI |
14 | Zeng Y, Zhong JM, Li LY, et al (1983). Follow-up studies on Epstein-Barr virus IgA/ VCA antibody-positive persons in Zangwu County, China. Intervirology, 20, 1990-4. |
15 | Zhang LW, Luo BQ, Dou XQ, et al (2012). Quantitative analysis of Epstein-Barr virus DNA in saliva, blood serum and peripheral blood cells in patients with nasopharyngeal carcinoma. Chin J Otorhinolaryngol Skull Base Surg, 18, 24-7. |
16 | Zhang Y, Gao HY, Feng HX, et al (2004). Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal Carcinoma. Natl Med J Chin, 84, 982-6. |
17 | Zhu HF, He X (2012). Significance of detecting plasma EBV DNA and VCA-IgA in patients with nasopharyngeal carcinoma. J Chin Oncol, 18, 111-3. |
18 | Chan KCA, Lo YMD (2002). Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Cancer Biol, 12, 489-96. DOI |
19 | Chan ATC, Lo YMD, Zee B, et al (2002). Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst, 94, 1614-9. DOI |
20 | Chang KP, Hsu CL, Chang YL, et al (2008). Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol, 44, 784-92. DOI ScienceOn |
21 | Chan KH, Gu YL, Ng F, et al (2003). EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer, 105, 706-9. DOI |
22 | Fan H, Nicholls J, Chua D, et al (2004). Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer, 112, 103641. |
23 | Feng HY, Huang YJ, Zhou XY, et al (2009). Diagnosis of NPC with Plasma EBV DNA. Journal of Tropical Medicine, 9, 913-5. |
24 | Kong P (2010). The clinical value of the quantitative determination of EBV-DNA in blood serum and PBMC patients with nasopharyngeal carcinoma. J Shandong Med College, 32, 321-4. |
25 | Shotelersuk K, Khorprasert C, Sakdikul S, et al (2000). Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res, 6, 1046-51. |
26 | Ng WT, Choi CW, Lee MC, et al (2010). Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer, 9, 221-8. DOI |
27 | Shao JY, Zhang Y, Li YH, et a1 (2004). Comparison of Epstein- Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res, 24, 4059-66. |
28 | Sharma TD, Singh TT, Laishram RS, et al (2011).Nasopharyngeal carcinoma--a clinico-pathological study in a regional cancer centre of northeastern India. Asian Pac J Cancer Prev, 12, 1583-7. |
29 | Sun JG, Wang HX, Xiao FG, et al (2010). Clinical application of plasma ell free EBV DNA, serum CYFR A21-1 and VCAIgA in patients with nasopharyngeal carcinoma. Modern Oncology, 18, 1930-2. |
30 | Sun JG, Zheng AP (2008). Clinical significance of plasma EBV DNA and VCA-IgA for nasopharyngeal carcinoma. Modern Oncol, 16, 2086-7. |
31 | Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. DOI ScienceOn |
32 | Tan YJ, Su XK, Cui JH (2010). Comparison of detection of serum VCA-lgA, EA-IgA and EBV-DNA in nasopharyngeal carcinoma patient. Chongqing Med J, 39, 703-6. |
33 | Tsang RK, Vlantis AC, Ho RW, et al (2004). Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck, 26, 598-602. DOI ScienceOn |
34 | Wei K, Xu Y, Liu J, Zhang W, Liang Z (2010). No incidence trends and no change in pathological proportions of nasopharyngeal carcinoma in Zhongshan in 1970-2007. Asian Pac J Cancer Prev, 11, 1595-9. |
35 | Zong YS, Sham JS, Ng MH, et al (1992). Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer, 69, 3-7. DOI |